Stocks and Investing
by (remove) : Paul Knight
RSSJSONXMLCSV
Stocks and Investing
by (remove) : Paul Knight
RSSJSONXMLCSV
Tue, February 13, 2024
Fri, December 8, 2023
Wed, November 1, 2023
Thu, October 26, 2023
Wed, August 30, 2023
Mon, August 21, 2023
Fri, July 28, 2023
Wed, July 12, 2023
Thu, May 25, 2023
Wed, May 24, 2023
Wed, May 10, 2023
Fri, May 5, 2023
Tue, March 14, 2023
Fri, March 3, 2023
Fri, February 17, 2023
Fri, February 3, 2023
Fri, December 2, 2022
Tue, November 22, 2022
Fri, October 28, 2022
Mon, October 24, 2022
Thu, September 15, 2022
Thu, June 2, 2022
Fri, May 13, 2022
Wed, May 11, 2022
Tue, May 10, 2022
Thu, May 5, 2022
Fri, April 29, 2022
Fri, March 25, 2022
Wed, December 8, 2021
Thu, November 11, 2021
Mon, September 20, 2021
Wed, September 15, 2021
Thu, September 9, 2021
Wed, August 18, 2021
Fri, August 13, 2021
Tue, August 10, 2021
Fri, July 30, 2021
Mon, July 12, 2021
Wed, June 30, 2021
Wed, May 26, 2021
Tue, March 23, 2021
Thu, March 18, 2021
Tue, March 2, 2021
Wed, February 17, 2021
Tue, January 19, 2021
Fri, January 8, 2021
Tue, November 10, 2020
Tue, July 2, 2019
Tue, June 11, 2019
Thu, November 29, 2018
Tue, July 17, 2018
Tue, November 7, 2017
Mon, May 1, 2017
Mon, March 27, 2017
Tue, November 29, 2016
Tue, May 3, 2016
Thu, August 15, 2013

Paul Knight Maintained (WST) at Buy with Increased Target to $470 on, Feb 13th, 2024


Published on 2024-10-28 08:55:54 - WOPRAI, Paul Knight
  Print publication without navigation


Paul Knight of Keybanc, Maintained "West Pharmaceutical Services, Inc." (WST) at Buy with Increased Target from $440 to $470 on, Feb 13th, 2024.

Paul has made no other calls on WST in the last 4 months.



There are 2 other peers that have a rating on WST. Out of the 2 peers that are also analyzing WST, 0 agree with Paul's Rating of Hold.



These are the ratings of the 2 analyists that currently disagree with Paul


  • David Windley of "Jefferies" Upgraded from Hold to Strong Buy and Increased Target to $536 on, Wednesday, February 7th, 2024
  • Jacob Johnson of "Stephens & Co." Maintained at Buy with Decreased Target to $390 on, Friday, October 27th, 2023
Contributing Sources